{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:19:46Z","timestamp":1784744386343,"version":"3.55.0"},"reference-count":37,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.20010","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T22:05:39Z","timestamp":1594159539000},"page":"78-86","source":"Crossref","is-referenced-by-count":17,"title":["Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma"],"prefix":"10.3960","volume":"60","author":[{"given":"Akio","family":"Sakatani","sequence":"first","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"},{"name":"Department of Pathology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okatani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"},{"name":"Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Asaoku","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"},{"name":"Division of Pathophysiology, Okayama University Graduate School of Health Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Stein H, Pileri SA, Weiss LM, et al. Hodgkin lymphomas. In: Swerdlow SH, Campo E, Harris LH, <i>et al<\/i>. (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, IARC Press. 2017; pp. 424-442."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Aoki R, Karube K, Sugita Y <i>et al.<\/i> Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001\u20132006. Pathol Int. 2008; 58: 174-182.","DOI":"10.1111\/j.1440-1827.2007.02207.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Engert A, Ballova V, Haverkamp H <i>et al.<\/i> Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol. 2005; 23: 5052-5060.","DOI":"10.1200\/JCO.2005.11.080"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Bonadonna G, Bonfante V, Viviani S <i>et al.<\/i> ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol. 2004; 22: 2835-2841.","DOI":"10.1200\/JCO.2004.12.170"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Ogura M, Itoh K, Kinoshita T <i>et al.<\/i> Phase II study of ABVd therapy for newly diagnosed clinical stage II\u2013IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010; 92: 713-724.","DOI":"10.1007\/s12185-010-0712-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Duggan DB, Petroni GR, Johnson JL <i>et al.<\/i> Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial. J Clin Oncol. 2003; 21: 607-614.","DOI":"10.1200\/JCO.2003.12.086"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tzankov A, Bourgau C, Kaiser A <i>et al.<\/i> Rare expression of T-cell markers in classical Hodgkin\u2019s lymphoma. Mod Pathol. 2005; 18: 1542-1549.","DOI":"10.1038\/modpathol.3800473"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Asano N, Kinoshita T, Tamaru J <i>et al.<\/i> Cytotoxic molecule-positive classical Hodgkin\u2019s lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type. Haematologica. 2011; 96: 1636-1643.","DOI":"10.3324\/haematol.2011.041079"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Marafioti T, Hummel M, Foss HD <i>et al.<\/i> Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000; 95: 1443-1450.","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450"},{"key":"10","unstructured":"10 Carbone A, Gloghini A, Gaidano G <i>et al.<\/i> Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin\u2019s disease. Blood. 1998; 92: 2220-2228."},{"key":"11","unstructured":"11 Br\u00e4uninger A, Wacker HH, Rajewsky K, K\u00fcppers R, Hansmann ML. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin\u2019s lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin\u2019s lymphoma. Cancer Res. 2003; 63: 1644-1651."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 K\u00fcppers R. The biology of Hodgkin\u2019s lymphoma. Nat Rev Cancer. 2009; 9: 15-27.","DOI":"10.1038\/nrc2542"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Montalb\u00e1n C, Garc\u00eda JF, Abraira V <i>et al.<\/i> Influence of biologic markers on the outcome of Hodgkin\u2019s lymphoma: a study by the Spanish Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol. 2004; 22: 1664-1673.","DOI":"10.1200\/JCO.2004.06.105"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan\u2013B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003; 120: 767-777.","DOI":"10.1309\/YCH8DWUFFQBKGPVB"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Garc\u00eda-Cos\u00edo M, Sant\u00f3n A, Mart\u00edn P <i>et al.<\/i> Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin\u2019s lymphoma. Mod Pathol. 2004; 17: 1531-1538.","DOI":"10.1038\/modpathol.3800227"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tzankov A, Zimpfer A, Pehrs AC <i>et al.<\/i> Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol. 2003; 16: 1141-1147.","DOI":"10.1097\/01.MP.0000093627.51090.3F"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Hoeller S, Zihler D, Zlobec I <i>et al.<\/i> BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin\u2019s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology. 2010; 56: 217-228.","DOI":"10.1111\/j.1365-2559.2009.03462.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Watanabe K, Yamashita Y, Nakayama A <i>et al.<\/i> Varied B-cell immunophenotypes of Hodgkin\/Reed-Sternberg cells in classic Hodgkin\u2019s disease. Histopathology. 2000; 36: 353-361.","DOI":"10.1046\/j.1365-2559.2000.00830.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Schwering I, Br\u00e4uninger A, Klein U <i>et al.<\/i> Loss of the B-lineage\u2013specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003; 101: 1505-1512.","DOI":"10.1182\/blood-2002-03-0839"},{"key":"20","unstructured":"20 S\u00e1ez AI, Artiga MJ, S\u00e1nchez-Beato M <i>et al.<\/i> Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1\/OBF.1 in lymphomas. Mod Pathol. 2002; 15: 211-220."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Cheson BD, Fisher RI, Barrington SF <i>et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3067.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Korkolopoulou P, Cordell J, Jones M <i>et al.<\/i> The expression of the B-cell marker mb-1 (CD79a) in Hodgkin\u2019s disease. Histopathology. 1994; 24: 511-515.","DOI":"10.1111\/j.1365-2559.1994.tb00568.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Valsami S, Pappa V, Rontogianni D <i>et al.<\/i> A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin\u2019s lymphoma: a potential prognostic role of MUM1\/IRF4. Haematologica. 2007; 92: 1343-1350.","DOI":"10.3324\/haematol.11523"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Di Napoli A, Al-Jadiri MF, Talerico C <i>et al.<\/i> Epstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin\/Reed-Sternberg cells. Pediatr Blood Cancer. 2013; 60: 2068-2072.","DOI":"10.1002\/pbc.24654"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Elsayed AA, Satou A, Eladl AE <i>et al.<\/i> Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases. Histopathology. 2017; 70: 579-594.","DOI":"10.1111\/his.13100"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Elsayed AA, Asano N, Ohshima K <i>et al.<\/i> Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: A clinicopathologic study. Pathol Int. 2014; 64: 336-345.","DOI":"10.1111\/pin.12175"},{"key":"27","unstructured":"27 von Wasielewski R, Mengel M, Fischer R <i>et al.<\/i> Classical Hodgkin\u2019s disease. Clinical impact of the immunophenotype. Am J Pathol. 1997; 151: 1123-1130."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Aldred V, Vassallo J, Froes M. Campos AHJ, Augusto Soares F. CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients. Leuk Lymphoma. 2008; 49: 2198-2202.","DOI":"10.1080\/10428190802239170"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Benharroch D, Nalbandyan K, Lazarev I. CD20 over-expression in Hodgkin-Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest. J Cancer. 2015; 6: 1155-1159.","DOI":"10.7150\/jca.13107"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shimabukuro-Vornhagen A, Haverkamp H, Engert A <i>et al.<\/i> Lymphocyte-rich classical Hodgkin\u2019s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials. J Clin Oncol. 2005; 23: 5739-5745.","DOI":"10.1200\/JCO.2005.17.970"},{"key":"31","unstructured":"31 Clarke C, O\u2019Malley C, Glaser S. Chapter 27 Hodgkin Lymphoma. In: Ries LAG, Young JL, Keel GE, <i>et al<\/i>. (eds): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Pub. No. 07-6215, Bethesda, MD, NIH Pub. 2007; pp. 228-234."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Ichiki A, Carreras J, Miyaoka M <i>et al.<\/i> Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans Classifier. J Clin Exp Hematop. 2017; 57: 54-63.","DOI":"10.3960\/jslrt.17029"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Morito T, Fujihara M, Asaoku H <i>et al.<\/i> Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci. 2009; 100: 1255-1260.","DOI":"10.1111\/j.1349-7006.2009.01167.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Sarkozy C, Molina T, Ghesqui\u00e8res H <i>et al.<\/i> Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica. 2017; 102: 150-159.","DOI":"10.3324\/haematol.2016.152256"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Gualco G, Natkunam Y, Bacchi CE. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol. 2012; 25: 661-674.","DOI":"10.1038\/modpathol.2011.200"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Parker K, Venkataraman G. Challenges in the diagnosis of gray zone lymphomas. Surg Pathol Clin. 2019; 12: 709-718.","DOI":"10.1016\/j.path.2019.03.014"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Evens AM, Kanakry JA, Sehn LH <i>et al.<\/i> Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015; 90: 778-783.","DOI":"10.1002\/ajh.24082"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/3\/60_20010\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T17:36:48Z","timestamp":1616521008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/3\/60_20010\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20010","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}